Full Press Release Details
Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments
OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) --Daxor Corporation (Nasdaq: DXR), theglobal leader in blood volume measurement technology, today announces significant commercial momentum and clinical validation following the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The company’s successful debut of itsnewly FDA-cleared, next-generation BVA analyzersignals a new era of data-driven fluid management for amulti-billion-dollar market.
The initial response from clinicians confirmed robust market demand for the new system, driven by its enhancedease of use, speed, and over 95% accuracy.
New Clinical Data Validates Commercial Opportunity
During the meeting, new clinical data presented from three leading institutions furthervalidated Daxor’s BVA technologyacross critical,high-cost patient populations:
“The data presented at HFSA, particularly the clinical findings showingzero unplanned readmissionsfor optimally managed patients, providesundeniable evidence that BVA isan essential diagnostic for improving care and reducing costs,” said John L. Jefferies, MD, MPH, MBA, Chief Medical Officer of Daxor Corporation. “Coupling thisoverwhelming clinical validationwith our faster, more accessible analyzer means Daxor is nowideally positioned tocapture a significant commercial shareof thismulti-billion-dollar market.”
About Daxor Corporation
Daxor Corporation (NASDAQ: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
For more information, please visit our website atDaxor.com.
Sign up to receive news on Daxor’s innovative technologyHERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact: